Indication
EGFR Negative Non-Small Cell Lung Cancer
2 clinical trials
1 product
2 drugs
Clinical trial
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Drug
AtezolizumabDrug
DocetaxelClinical trial
Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III TrialStatus: Recruiting, Estimated PCD: 2024-10-31
Product
PD-1